| Â | Â | Â | Â | Lung grade |
|---|
Group | 17AAG dose (mg/kg-d) | Body weight (g) | Lung weight (g) |
+
|
++
|
+++
|
|---|
1 (n = 8) | Vehicle only | 17.79 ± 1.88 | 0.477 ± 0.19 | 2 (25%) | 3 (37.5%) | 3 (37.5%) |
2 (n = 10) | 20 | 19.88 ± 1.68* | 0.412 ± 0.17 | 3 (30%) | 2 (20%) | 5 (50%) |
3 (n = 10§) | 60 | 20.17 ± 0.89* | 0.276 ± 0.11* | 8 (80%) | 2 (20%) | 0 |
- *Compared with group 1; Student's t test was used (p < 0.05)
- §Compared with group 1; Chi-square was used for statistical analysis P < 0.05.
- For drug testing in the lung metastasis model, 28 nude mice (6-week-old females) were divided into three groups: a control group (n = 8), and 17AAG groups treated with either 20 mg/kg (n = 10) or 60 mg/kg (n = 10). Each mouse received a single intravenous tail vein injection of 106 DBM2 cells in 100 μl PBS. Treatment started the second day after the cells were injected and continued for 8 weeks, by which time most of the control mice were moribund. At necropsy, lungs were harvested and scored; body weight and lung weight of each mouse were also recorded.
